1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
SciVision Biotech Inc.

SciVision Biotech Inc.

TTWSE:1786
39.70
TWD
-0.15
(-0.38%)
2.31EPS
22.20P/E
3.93BMarket Cap
Oct 29Next Earn
SciVision Biotech Inc.
TWSE:1786
(Taiwan Stock Exchange)

Recent

price

39.70

P/E

ratio

22.20

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
1.51
2.8
3.8
3.72
2.54
4.34
3.81
4.31
5.53
6.66
7.05
7.64
8.42
10.67
12.78
12.24
12.08
Revenue per Share
-0.16
1
1.19
0.75
-0.36
0.9
-0.44
0.29
1.46
1.84
1.93
1.54
2.14
2.66
3.51
2.24
2.42
Basic EPS, GAAP
-0.37
0.32
0.73
0.18
-2
-2.55
-3.2
-5.14
0.27
0.04
0.9
1.1
2.52
3.85
3.4
0.31
0.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.56
- -
0.43
- -
0.17
1.41
1.2
0.88
1.42
1.99
2.45
3.23
- -
Dividend per Share
2.12
6.78
7.93
17.43
17.74
15.55
14.91
15.24
17.46
20.56
21.21
21.9
22.83
24.02
26.42
26.46
24.42
Book Value per Share
2.11
6.77
7.93
17.41
17.72
15.52
14.8
15.15
17.37
20.47
21.15
21.85
22.79
23.99
26.4
26.45
24.4
Tangible Book Value per Share
44
51
53
54
62
61
60
60
60
66
66
66
66
67
69
72
74
Basic Weighted Avg Shares
66
143
201
201
158
265
228
258
330
438
467
506
557
713
883
887
889
Sales/Revenue/Turnover
-41.82
25.07
25.45
14.87
-22.34
15.16
12.18
12.05
24.47
30.65
31.41
24.12
24.15
28
28.09
21.42
16.46
Operating Margin (%)
21
22
22
23
19
20
21
21
21
15
15
53
62
63
65
80
88
Depreciation Expense
-7
51
63
40
-22
55
-26
17
87
121
128
102
142
178
242
162
178
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
24.4
6.69
10.11
16.06
12.35
18.34
15.28
16.92
12.27
14.11
Effective Tax Rate (%)
-10.37
35.71
31.15
20.12
-13.99
20.71
-11.5
6.63
26.36
27.57
27.42
20.12
25.43
24.95
27.43
18.31
20.03
Profit Margin (%)
-5
249
310
938
768
498
399
266
313
397
432
500
753
859
829
1,253
1,098
Working Capital
13
- -
- -
- -
- -
25
229
422
363
310
320
328
411
347
85
474
475
LT Debt
112
357
418
1,084
1,023
949
894
914
1,078
1,361
1,404
1,450
1,511
1,627
1,897
1,980
1,787
Total Equity
- -
- -
- -
- -
- -
- -
- -
1.8
5.13
7.54
7.2
5.59
5.46
8.63
10.02
7.24
5.92
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
1.55
6.1
7.93
7.89
5.71
7.33
9.48
12.06
7.38
8.9
Return on Capital (%)
-7.01
21.81
16.11
5.37
-2.1
5.56
-2.85
1.9
8.72
9.9
9.26
7.13
9.57
11.34
13.75
8.37
10.16
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
10
10
LT Borrowings
374
376
379
LT Finance Leases
101
98
97
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
73
Market Capitalization
5,432
4,677
3,929

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,427
1,527
1,299
Cash, Cash Equivalents & STI
1,054
1,092
906
Accounts Receivable, Net
240
288
220
Inventories
82
99
91
Total Current Liabilities
175
373
201
Payables & Accruals
- -
- -
- -
ST Debt
11
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.99%
7.22%
4.38%
Free Cash Flow
242.1%
21.28%
-90.54%
Net Income, GAAP
18.62%
9.5%
-32.99%
Sales/Revenue/Turnover
13.71%
14.14%
0.37%
Total Cash Common Dividend
- -
28.27%
38.12%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
195
211
222
255
883
2025
204
209
221
251
887
2026
205
211
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
1
0.82
0.92
3.51
2025
0.79
-0.22
0.81
0.87
2.24
2026
0.29
0.47
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.45
2025
- -
- -
- -
- -
3.23
2026
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
SciVision Biotech Inc. (1786.TW) manufactures and sells hyaluronic acid-based medical products utilizing its proprietary Cross-Linked Hyaluronic Acid Platform (CHAP) technology; core offerings include hyaluronic acid dermal fillers such as Hya-Dermis for facial aesthetics and plastic surgery, synovial fluid supplements like Hya-Joint for orthopedic joint cavity injections and knee osteoarthritis treatment, absorbable adhesion barriers for surgical applications, and intravesical instillation products for urology. The company also engages in wholesale of medical equipment and provides management consulting services. Founded in 2001 and headquartered in Kaohsiung, Taiwan, with production facilities in the Kaohsiung Cianjhen Technology Industrial Park compliant with ISO 13485, US FDA, and PIC/s GMP standards, SciVision Biotech operates in the Americas, Europe, Asia, Middle East, and Africa, serving medical, aesthetic, orthopedic, surgical, and urological markets. Recent developments include overseas market expansion into Russia, with hyaluronic acid dermal fillers contributing to revenue starting in the fourth quarter of 2025. The company maintains 64 employees and reported trailing twelve-month revenue of TWD 891.22 million and net income of TWD 163.57 million as of late 2025.